0001140361-20-026715.txt : 20201127 0001140361-20-026715.hdr.sgml : 20201127 20201127160522 ACCESSION NUMBER: 0001140361-20-026715 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201127 DATE AS OF CHANGE: 20201127 EFFECTIVENESS DATE: 20201127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia, Inc. CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 201355359 BUSINESS ADDRESS: STREET 1: 1000 SIERRA POINT PARKWAY CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 1000 SIERRA POINT PARKWAY CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: MyoKardia Inc DATE OF NAME CHANGE: 20120618 15-12B 1 nt10017439x1_1512b.htm 15-12B

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 15


 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number 001-37609



MYOKARDIA, INC.
(Exact name of registrant as specified in its charter)



1000 Sierra Point Parkway
Brisbane, CA 94005
(650) 741-0900
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)



Place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
 
Rule 12g-4(a)(2)
 
Rule 12h-3(b)(1)(i)
 
Rule 12h-3(b)(1)(ii)
 
Rule 15d-6
 
Rule 15d-22(b)
 

Approximate number of holders of record as of the certification or notice date: one (1).

Pursuant to the requirements of the Securities Exchange Act of 1934, MyoKardia, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: November 27, 2020
By:
/s/ Katherine R. Kelly
 
Name: Katherine R. Kelly
Title: Vice President and Secretary